How should an intubated patient with myasthenia gravis be managed in the intensive care unit?

Management of Intubated Myasthenia Gravis Patients in the ICU

If neuromuscular blocking agents (NMBAs) are required in an intubated myasthenia gravis patient, use reduced doses guided by peripheral nerve stimulation with train-of-four (TOF) monitoring, as these patients have markedly increased sensitivity to non-depolarizing NMBAs due to reduced functional nicotinic receptors 1.

Critical NMBA Considerations

Dosing Requirements

• Myasthenia gravis patients require significantly reduced NMBA doses compared to standard dosing due to antibody-mediated reduction in functional nicotinic receptors 1
• Baseline neuromuscular function assessment before NMBA administration may reveal impaired transmission, necessitating even lower doses 1
• Sensitivity to NMBAs varies greatly among myasthenia patients—individual assessment is mandatory 1

Monitoring

• Mandatory use of peripheral nerve stimulation with TOF monitoring to guide dosing 1
• While no specific muscle group is definitively recommended for monitoring (insufficient evidence), TOF monitoring of the adductor pollicis muscle has been studied 1
• Patients with primarily ocular disease may require higher NMBA doses than those with generalized disease 1

Drug-Specific Warnings

• Avoid succinylcholine in patients on cholinesterase inhibitors (pyridostigmine) due to prolonged neuromuscular blockade from reduced plasma cholinesterase activity 1
• Avoid mivacurium as pyridostigmine inhibits its metabolism and delays recovery 1
• Do not discontinue cholinesterase inhibitors on the day of intubation as this increases respiratory distress risk 1

General ICU Management Principles

Respiratory Management

• Early intubation is recommended when respiratory failure is imminent—this is the most important step in myasthenic crisis management 2
• Orotracheal intubation is preferred 2
• Median ventilation duration is 12-14 days under adequate treatment 3
• Consider early tracheostomy (within 10 days) if prolonged ventilation is anticipated, as this correlates with shorter mechanical ventilation duration (26.2 vs 42.0 days) and ICU length of stay (26.2 vs 42.3 days) 4

Cholinesterase Inhibitor Management

• Discontinue pyridostigmine/neostigmine during acute crisis while intubated 5, 3
• Resume cholinesterase inhibitors prior to extubation 5
• Small bore duodenal feeding tubes are preferred over nasogastric tubes to decrease aspiration risk 2

Immunotherapy

• Plasma exchange is more effective than IVIG for myasthenic crisis with respiratory failure 2
• Initiate or optimize immunosuppression with corticosteroids once airway is secured 5
• Steroid dosage can be increased after intubation 5
• Consider azathioprine or rituximab for long-term immunosuppression 3

Metabolic Management

• Target blood glucose <180 mg/dL in patients receiving NMBAs 1
• Lower targets (100-150 mg/dL) may be beneficial if achievable without hypoglycemia risk, though data are insufficient for firm recommendation 1
• Intensive insulin therapy may reduce critical illness polyneuromyopathy risk but increases hypoglycemia risk 1

Supportive Care

• Structured physiotherapy regimen for patients on continuous NMBA infusions 1
• Aggressive treatment of precipitating infections 5, 3
• Monitor for complications including dysautonomia, aspiration, and delirium 3
• Hemodynamic monitoring is essential 5

Common Pitfalls to Avoid

1. Using standard NMBA doses—this will cause prolonged paralysis and delayed recovery
2. Failing to use TOF monitoring—blind dosing is dangerous in this population
3. Discontinuing cholinesterase inhibitors too early—resume before extubation attempts
4. Delaying tracheostomy—early tracheostomy (≤10 days) significantly reduces ventilation time and ICU stay 4
5. Using succinylcholine or mivacurium—these have prolonged effects in myasthenia patients on cholinesterase inhibitors

Prognostic Factors

• Mortality ranges from 2-16%, primarily from complications rather than the crisis itself 3
• Older age is an independent negative predictor of survival 6
• Multiple comorbidities and mechanical ventilation predict higher complication rates 6
• Patients not requiring mechanical ventilation have good outcomes 6
• 30% lifetime risk of crisis recurrence 3